Proactive assessment of patient reported outcomes in ovarian cancer studies: a systematic review and call for action in future studies
Ainhoa Madariaga(Hospital Universitario 12 De Octubre), Amit M. Oza(Ontario Institute for Cancer Research), David Valcárcel(Vall d'Hebron Hospital Universitari), Manuel Alva(Hospital Universitario 12 De Octubre), Lawrence Kasherman(The University of Sydney), Cristina González-Deza(Hospital Universitario 12 De Octubre), Luís Manso(Research Institute Hospital 12 de Octubre), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Eva Ciruelos(Hospital Universitario 12 De Octubre), Stephanie Lheureux(Princess Margaret Cancer Centre), Pablo Tolosa(Research Institute Hospital 12 de Octubre), Laura Lema(Hospital Universitario 12 De Octubre), José Manuel Estrada Lorenzo(Research Institute Hospital 12 de Octubre)
Cited by 1
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k